{"id":3259,"date":"2025-06-13T16:10:58","date_gmt":"2025-06-13T16:10:58","guid":{"rendered":"https:\/\/vantagebiotrials.com\/?p=3259"},"modified":"2025-10-02T13:44:08","modified_gmt":"2025-10-02T13:44:08","slug":"vantage-biotrials-recognized-as-finalist-for-the-2025-partnership-award","status":"publish","type":"post","link":"https:\/\/vantagebiotrials.com\/fr\/vantage-biotrials-recognized-as-finalist-for-the-2025-partnership-award\/","title":{"rendered":"Vantage BioTrials Recognized as Finalist for the 2025 Partnership Award"},"content":{"rendered":"<p><strong><img decoding=\"async\" class=\"aligncenter\" src=\"https:\/\/vantagebiotrials.com\/wp-content\/uploads\/2023\/11\/logo-post.png\" alt=\"\" width=\"305\" height=\"130\" \/><\/strong><\/p>\n<p><strong>June 11, 2025, Montr\u00e9al, Canada<\/strong> \u2013 Vantage BioTrials is proud to announce that it has been named a finalist for the esteemed 2025 Partnership Award, a prestigious award recognizing outstanding collaborative projects within Quebec\u2019s innovation ecosystem. This accolade celebrates the successful partnership between Vantage BioTrials, Groupe Sorintellis, and the Centre de Recherche Informatique de Montr\u00e9al (CRIM), underscoring a shared commitment to advancing clinical research through innovation and excellence.<\/p>\n<p>The Partnership Award finalist status highlights the strength and impact of this strategic collaboration, which combines Vantage BioTrials\u2019 expertise in clinical trial management with Groupe Sorintellis and CRIM\u2019s cutting-edge technological capabilities. Together, they have developed innovative solutions that enhance the quality, efficiency, and risk management of clinical trials, ultimately accelerating the delivery of life-saving therapies to patients.<\/p>\n<p>At the core of this partnership lies Vantage BioTrials\u2019 commitment to Quality by Design (QbD) and Risk-Based Management (RBM) principles. By integrating these methodologies, the team ensures that clinical trials are meticulously planned, monitored, and optimized from inception to completion, delivering robust data integrity and regulatory compliance while reducing costs and timelines.<\/p>\n<p>\u201cWe are truly honored to be recognized among such talented and visionary partners,\u201d said Vatche Bartekian, President of Vantage BioTrials. \u201cThis nomination reflects not only the strength of our partnership but also our dedication to driving innovation in clinical research, supporting our clients\u2019 goals, and ultimately improving patient outcomes.\u201d<\/p>\n<p>As a finalist for the Partnership Award, Vantage BioTrials continues to demonstrate leadership within Quebec\u2019s vibrant life sciences and technology sectors. The company looks forward to continuing its collaboration with Groupe Sorintellis and CRIM, contributing to a stronger, more innovative clinical research environment.<\/p>\n<p><strong>About Vantage BioTrials Inc.<\/strong><\/p>\n<p>Vantage BioTrials is a Contract Research Organization that uses innovative clinical trial management strategies for the life science industry with a focus on patient safety &amp; advancing new therapies to market. We offer pharmaceutical, biotech &amp; medical device companies a complete and integrated set of full service clinical trial management solutions at a competitive value.<\/p>\n<p>For more information about Vantage BioTrials\u2019 services and capabilities, please visit <a href=\"http:\/\/www.vantagebiotrials.com\/\">www.vantagebiotrials.com<\/a>.<\/p>\n<p><strong>\u00a0<\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>June 11, 2025, Montr\u00e9al, Canada \u2013 Vantage BioTrials is proud to announce that it has been named a finalist for the esteemed 2025 Partnership Award, a prestigious award recognizing outstanding collaborative projects within Quebec\u2019s innovation ecosystem. This accolade celebrates the successful partnership between Vantage BioTrials, Groupe Sorintellis, and the Centre de Recherche Informatique de Montr\u00e9al (CRIM), underscoring a shared commitment to advancing clinical research through innovation and excellence. The Partnership Award finalist status highlights the strength and impact of this strategic collaboration, which combines Vantage BioTrials\u2019 expertise in clinical trial management with Groupe Sorintellis and CRIM\u2019s cutting-edge technological capabilities. Together, they have developed innovative solutions that enhance the quality, efficiency, and risk management of clinical trials, ultimately accelerating the delivery of life-saving therapies to patients. At the core of this partnership lies Vantage BioTrials\u2019 commitment to Quality by Design (QbD) and Risk-Based Management (RBM) principles. By integrating these methodologies, the team ensures that clinical trials are meticulously planned, monitored, and optimized from inception to completion, delivering robust data integrity and regulatory compliance while reducing costs and timelines. \u201cWe are truly honored to be recognized among such talented and visionary partners,\u201d said Vatche Bartekian, President of Vantage BioTrials. \u201cThis nomination reflects not only the strength of our partnership but also our dedication to driving innovation in clinical research, supporting our clients\u2019 goals, and ultimately improving patient outcomes.\u201d As a finalist for the Partnership Award, Vantage BioTrials continues to demonstrate leadership within Quebec\u2019s vibrant life sciences and technology sectors. The company looks forward to continuing its collaboration with Groupe Sorintellis and CRIM, contributing to a stronger, more innovative clinical research environment. About Vantage BioTrials Inc. Vantage BioTrials is a Contract Research Organization that uses innovative clinical trial management strategies for the life science industry with a focus on patient safety &amp; advancing new therapies to market. We offer pharmaceutical, biotech &amp; medical device companies a complete and integrated set of full service clinical trial management solutions at a competitive value. For more information about Vantage BioTrials\u2019 services and capabilities, please visit www.vantagebiotrials.com. \u00a0<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[18,20],"tags":[],"class_list":["post-3259","post","type-post","status-publish","format-standard","hentry","category-news-homepage","category-news-pressroom","cms-no-post-thumbnail"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/3259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/comments?post=3259"}],"version-history":[{"count":0,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/posts\/3259\/revisions"}],"wp:attachment":[{"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/media?parent=3259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/categories?post=3259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vantagebiotrials.com\/fr\/wp-json\/wp\/v2\/tags?post=3259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}